Revenue projections to 2028
Vaccines Worldwide – Highlights
- Revenue in the Vaccines market is projected to reach US$81.97bn in 2023.
- Revenue is expected to show an annual growth rate (CAGR 2023-2028) of -1.32%, resulting in a market volume of US$76.72bn by 2028.
- In global comparison, most revenue will be generated in the United States (US$28,090.00m in 2023).1
How much do vaccines cost?
The image below represents a tiny sample of the prices paid for vaccines by the CDC and by the private sector.
… Contract prices are those for CDC vaccine contracts that are established for the purchase of vaccines by immunization programs that receive CDC immunization cooperative agreement funds (i.e., state health departments, certain large city immunization projects, and certain current and former U.S. territories) … Private sector prices are those reported by vaccine manufacturers annually to CDC…
The complete pediatric and adult price lists, including for COVID vaccines, can be found at: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html
Vaccine manufacturers’ post-COVID earnings decline
Stocks of Pfizer and other Covid vaccine makers like BioNTech and Moderna fell in premarket trading . . . after the company slashed its revenue forecasts . . ., a change in fortune for the sector as demand for the pandemic-related products that propelled them to record profits last year plummets.23
Annual COVID shots may still provide blockbuster earnings
Moderna and Pfizer both have predicted the market will follow that of the flu vaccine market, implying about 50% of Americans may go for an annual jab. If this happens, we could be looking at blockbuster revenue for vaccine makers.4
|↑1||“Vaccines – Worldwide: Statista Market Forecast.” Statista, www.statista.com/outlook/hmo/pharmaceuticals/vaccines/worldwide|
|↑2||Hart, Robert. “Vaccine Stocks-Including Pfizer, Moderna, BioNTech And Novavax-Slide Amid Plummeting Demand.” Forbes Magazine, 17 Oct. 2023, www.forbes.com/sites/roberthart/2023/10/16/vaccine-stocks-including-pfizer-moderna-biontech-and-novavax-slide-amid-plummeting-demand/?sh=1e3c2a717099|
PREP Act does not protect from fraud
|↑4||Cimino, Adria. “The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?” The Motley Fool, 11 Oct. 2023, www.fool.com/investing/2023/10/11/vaccine-market-is-changing-shoud-you-invest/|